Protocol Ledger

NCT03792490 · Phase II · COMPLETED

Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS

Interventional Phase II clinical trial protocol NCT03792490 sponsored by University Medical Center Goettingen in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-20 Enrollment: 120 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03792490
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03792490
Protocol FieldVerified Registry Value
NCT IdentifierNCT03792490
Consolidated Lead SponsorUniversity Medical Center Goettingen
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment120 participants (ACTUAL)
Registered Start Date2019-02-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03792490
Hospital Research SiteLocationSite Profile
Charité Universitätsmedizin BerlinBerlin, GermanyOpen Hospital Dossier ->
Medizinische Hochschule HannoverHanover, GermanyOpen Hospital Dossier ->
Universitätsklinikum JenaJena, GermanyOpen Hospital Dossier ->
Universitätsklinikum LeipzigLeipzig, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI